Correction: Peptidoglycan Recognition Protein 1 Enhances Experimental Asthma by Promoting Th2 and Th17 and Limiting Regulatory T Cell and Plasmacytoid Dendritic Cell Responses

Shin Yong Park, Xuefang Jing, Dipika Gupta and Roman Dziarski

*J Immunol* 2013; 190:6708; doi: 10.4049/jimmunol.1390028
http://www.jimmunol.org/content/190/12/6708
Corrections


In Fig. 9D, the descriptions for the y axes should read $10^{-4}$ instead of $10^{-6}$. The corrected Fig. 9 is shown below. The figure legend is correct as published and is shown below for reference.

![Figure 9](http://www.jimmunol.org/cgi/doi/10.4049/jimmunol.1390028)

**FIGURE 9.** Depletion of pDC in vivo reverses attenuated asthma phenotype in HDM-sensitized *Pglyrp1^−/−* mice. *Pglyrp1^−/−* mice were treated with anti-pDC (anti-CD317) mAb or isotype control IgG during sensitization with HDM for 5 wk. Anti-pDC mAb reduced the numbers of pDC in vivo (A). Depletion of pDC increased the numbers of eosinophils, neutrophils, lymphocytes, and macrophages in BAL cells and lungs (B), increased lung airway resistance (C), increased numbers of CD4+ cells in BAL cells and CD4+, Th1, Th2, and Th17 cells in the lungs, and decreased the percentage of Treg cells in BAL cells and the lungs (D), measured by flow cytometry, with gating as shown in Figs. 7, 8A; means ± SEM of six mice per group; *p < 0.05; **p < 0.005; anti-pDC versus IgG.

www.jimmunol.org/cgi/doi/10.4049/jimmunol.1390028